IDO1 and non-small cell lung carcinoma: Recently, Tanizaki et al. showed that high AEC was significantly associated with better outcomes among patients with NSCLC treated with nivolumab [21], and Seeber et al. found that high IDO1 expression was associated with response to anti-PD-1 drugs in metastatic renal cell carcinoma [40].